Skip to main content
Livermore
Livermore
ZHEN

Avidity Partners Management LP

SEC CIK
0001791827
Latest filing
Aug 14, 2026

The latest 13F from Avidity Partners Management LP covers Q2 2026 (filed Aug 14, 2026): 45 long positions worth $624.4M. The top 10 holdings make up 81.9% of the portfolio, and the largest is Dianthus Therapeutics, Inc. (DNTH) at 32.8%. Livermore has 23 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
13
Est. +$39.5M
Added
11
Est. +$38.5M
Reduced
6
Est. −$16.9M
Sold out
13
Est. −$16.6M

Top 5 holdings

Share of this quarter's portfolio value

  1. DNTHDianthus Therapeutics, Inc.
    32.8%$205.1MHistory
  2. CGONCG Oncology, Inc.
    15.9%$99.4MHistory
  3. ORKAOruka Therapeutics, Inc.
    11.6%$72.4MHistory
  4. JBIOJade Biosciences, Inc.
    6.1%$37.8MHistory
  5. ELVNEnliven Therapeutics, Inc.
    4.5%$27.9MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. MOBIMobia Medical, Inc.
    +$10.7MNewHistory
  2. SENSSenseonics Holdings, Inc.
    +$9.09MNewHistory
  3. CGONCG Oncology, Inc.
    +$7.82MAddedHistory
  4. ELVNEnliven Therapeutics, Inc.
    +$7.61MAddedHistory
  5. JBIOJade Biosciences, Inc.
    +$6.67MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. JBIOJade Biosciences, Inc.
    +2.07 pp4.0% → 6.1%History
  2. MOBIMobia Medical, Inc.
    +1.71 pp0.0% → 1.7%History
  3. SENSSenseonics Holdings, Inc.
    +1.46 pp0.0% → 1.5%History
  4. ELVNEnliven Therapeutics, Inc.
    +1.29 pp3.2% → 4.5%History
  5. KPTIKaryopharm Therapeutics Inc.
    +0.92 pp0.5% → 1.4%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. TEVATeva Pharmaceutical Industries Ltd
    −$8.47MReducedHistory
  2. VIRVir Biotechnology, Inc.
    −$4.39MReducedHistory
  3. MDTMedtronic plc
    −$2.35MReducedHistory
  4. CNCCentene Corp
    −$2.29MSold outHistory
  5. NTRANatera, Inc.
    −$1.80MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. TEVATeva Pharmaceutical Industries Ltd
    −1.66 pp2.7% → 1.1%History
  2. MDTMedtronic plc
    −0.88 pp1.8% → 0.9%History
  3. VIRVir Biotechnology, Inc.
    −0.88 pp1.7% → 0.8%History
  4. CNCCentene Corp
    −0.46 pp0.5% → 0.0%History
  5. NTRANatera, Inc.
    −0.36 pp0.4% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$624.4M
+$130.6M (+26.5%) vs. prior quarter
Positions
45
0 vs. prior quarter
Top 10 concentration
81.9%
Top 10 as share of value
Turnover
6.0%
Q2 2026, one quarter
Average holding period
8.2 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $4.71B (Q4 2021)

Q1 2021: $3.58BQ2 2021: $3.70BQ3 2021: $3.92BQ4 2021: $4.71BQ1 2022: $4.51BQ2 2022: $4.36BQ3 2022: $4.60BQ4 2022: $4.28BQ1 2023: $3.01BQ2 2023: $2.86BQ3 2023: $2.48BQ4 2023: $2.61BQ1 2024: $2.81BQ2 2024: $2.35BQ3 2024: $1.96BQ4 2024: $1.00BQ1 2025: $484.9MQ2 2025: $498.8MQ3 2025: $439.4MQ4 2025: $346.7MQ1 2026: $493.8MQ2 2026: $624.4M
Q1 2021Q2 2026
13F filings of Avidity Partners Management LP by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202645$624.4MDNTHCGONORKAvs. Q1 2026SEC
Q1 2026May 28, 2026Amended45$493.8MDNTHCGONORKAvs. Q4 2025SEC
Q4 2025Feb 13, 202639$346.7MDNTHCGONJBIOvs. Q3 2025SEC
Q3 2025Nov 14, 202543$439.4MDNTHCGONMDTvs. Q2 2025SEC
Q2 2025Aug 14, 202555$498.8MCGONBSXNTRAvs. Q1 2025SEC
Q1 2025May 15, 202563$484.9MBSXDNTHUNHvs. Q4 2024SEC
Q4 2024Feb 14, 202561$1.00BDNTHBSXJANXvs. Q3 2024SEC
Q3 2024Nov 14, 202481$1.96BBSXDNTHISRGvs. Q2 2024SEC
Q2 2024Aug 14, 202485$2.35BISRGBSXNTRAvs. Q1 2024SEC
Q1 2024May 15, 202487$2.81BFUSNBSXARVNvs. Q4 2023SEC
Q4 2023Feb 14, 202472$2.61BARVNBSXTMOvs. Q3 2023SEC
Q3 2023Nov 14, 202383$2.48BBSXJAZZBDXvs. Q2 2023SEC
Q2 2023Aug 14, 202393$2.86BBDXKRTXJAZZvs. Q1 2023SEC
Q1 2023May 15, 202383$3.01BARVNSGRYBIOvs. Q4 2022SEC
Q4 2022Feb 14, 202384$4.28BARGXUTHRNBIXvs. Q3 2022SEC
Q3 2022Nov 14, 202296$4.60BLLYUTHRNBIXvs. Q2 2022SEC
Q2 2022Aug 15, 202282$4.36BAZNVRTXARGXvs. Q1 2022SEC
Q1 2022May 16, 202291$4.51BAZNABBVARVNvs. Q4 2021SEC
Q4 2021Feb 14, 202297$4.71BABBVZNTLARVNvs. Q3 2021SEC
Q3 2021Nov 15, 2021103$3.92BMRTXARVNABBVvs. Q2 2021SEC
Q2 2021Aug 16, 2021112$3.70BVRTXABBVARVNvs. Q1 2021SEC
Q1 2021May 17, 202193$3.58BABBVAZNAVTR–SEC

13D and 13G filings

Companies where Avidity Partners Management LP reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

6 companies, largest stake first.

Companies where Avidity Partners Management LP owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
IMUXImmunic, Inc.13G9.90%14.0M shares+5.10 ppfrom 4.80%Jan 16, 20247 filingsApr 17, 2026SEC
SCYXScynexis Inc13G/A9.90%4.43M shares0.00 ppfrom 9.90%Feb 16, 20218 filingsFeb 17, 2026SEC
CNTXContext Therapeutics Inc.13G/A8.70%8.30M shares−1.20 ppfrom 9.90%May 13, 20246 filingsMay 12, 2026SEC
SYRSSyros Pharmaceuticals, Inc.13G/A7.60%2.05M shares–Sep 20, 20225 filingsFeb 14, 2025SEC
KZRKezar Life Sciences, Inc.13G/A6.90%502.6K shares–Jan 3, 20224 filingsFeb 14, 2025SEC
CATXPerspective Therapeutics, Inc.13G5.30%6.05M shares+1.10 ppfrom 4.20%Nov 14, 20243 filingsMar 10, 2026SEC

Latest filings

111 filings on file made by Avidity Partners Management LP or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Avidity Partners Management LP
CompanyFiled (ET)FormStakeChangeEvent dateFiling
CNTXContext Therapeutics Inc.May 12, 20263:07 PM ET13G/A8.70%8.30M shares−1.20 ppfrom 9.90%Mar 31, 2026SEC
IMUXImmunic, Inc.Apr 17, 202610:13 AM ET13G9.90%14.0M shares+5.10 ppfrom 4.80%Feb 17, 2026SEC
CATXPerspective Therapeutics, Inc.Mar 10, 20268:36 PM ET13G5.30%6.05M shares+1.10 ppfrom 4.20%Feb 20, 2026SEC
SCYXScynexis IncFeb 17, 202610:19 AM ET13G/A9.90%4.43M shares0.00 ppfrom 9.90%Dec 31, 2025SEC
DNTHDianthus Therapeutics, Inc.Nov 19, 20259:15 PM ET13D/A4.90%2.10M shares−5.00 ppfrom 9.90%Below 5%Nov 17, 2025SEC
CNTXContext Therapeutics Inc.Nov 14, 20254:27 PM ET13G/A9.90%9.20M shares0.00 ppfrom 9.90%Sep 30, 2025SEC
SCYXScynexis IncNov 14, 20252:27 PM ET13G/A9.90%4.52M shares0.00 ppfrom 9.90%Sep 30, 2025SEC
IMUXImmunic, Inc.Nov 14, 20251:39 PM ET13G/A4.80%4.70M shares−1.10 ppfrom 5.90%Below 5%Sep 30, 2025SEC
KZRKezar Life Sciences, Inc.Nov 14, 20251:33 PM ET13G/A0.00%0 shares–Below 5%Sep 30, 2025SEC
IMUXImmunic, Inc.Aug 14, 20252:37 PM ET13G/A5.90%5.62M shares−0.70 ppfrom 6.60%Jun 30, 2025SEC
CNTXContext Therapeutics Inc.Aug 14, 20252:28 PM ET13G/A9.90%9.13M shares0.00 ppfrom 9.90%Jun 30, 2025SEC
IMUXImmunic, Inc.May 15, 20252:07 PM ET13G/A6.60%6.04M shares−3.30 ppfrom 9.90%Mar 31, 2025SEC
DNTHDianthus Therapeutics, Inc.Mar 19, 20259:30 PM ET13D/A9.90%3.38M shares–Mar 17, 2025SEC
KZRKezar Life Sciences, Inc.Feb 14, 202510:42 AM ET13G/A6.90%502.6K shares–Dec 31, 2024SEC
CATXPerspective Therapeutics, Inc.Feb 14, 202510:26 AM ET13G/A4.20%2.84M shares–Below 5%Dec 31, 2024SEC
SCYXScynexis IncFeb 14, 202510:21 AM ET13G/A9.90%4.21M shares–Dec 31, 2024SEC
IMUXImmunic, Inc.Feb 14, 202510:16 AM ET13G/A9.90%9.02M shares–Dec 31, 2024SEC
SYRSSyros Pharmaceuticals, Inc.Feb 14, 202510:10 AM ET13G/A7.60%2.05M shares–Dec 31, 2024SEC
CNTXContext Therapeutics Inc.Feb 14, 202510:02 AM ET13G/A9.90%7.78M shares–Dec 31, 2024SEC
DNTHDianthus Therapeutics, Inc.Dec 3, 202413D/AOld format–––SEC